Dordaviprone under FDA priority review for aggressive glioma type
The U.S. Food and Drug Administration (FDA) has agreed…
Glioma
KROS 101 can activate T-cells to target brain cancer in lab studies
An experimental immune-modulating therapy called KROS 101 was able…
